Indication | n | % |
New or changed T2 signal on MRI | 18 | 31 |
New or changed contrast enhancement on MRI | 16 | 28 |
Follow-up on prior 18F-DOPA scan | 9 | 16 |
Baseline evaluation | 4 | 7 |
Differentiation between tumor and nontumor | 4 | 7 |
T2 signal on MRI and clinical symptoms | 3 | 5 |
Contrast enhancement on MRI and clinical symptoms | 2 | 3 |
Clinical symptoms suggestive of recurrence | 2 | 3 |